Metabolomic and Methylation Pathways Associated with Black-White Disparity in Lethal Prostate Cancer
Abstract
This report concerns Year 1 of the award. The objective of this project is to determine if there are intrinsic biological differences in prostate cancer (PCa) phenotypes that contribute to the disparity in outcomes between African American (AA) and European American (EA) men. The project is a matched case-control study of biochemical recurrence (BCR) in AA and EA PCa patients based on evaluating metabolomics and epigenetic differences between the groups, using prostatic fluid as the substrate for measuring analytes. In each race group 65 cases with BCR occurring in less than 5 years are matched on age and year of prostatectomy to 65 PCa patients without BCR for 5 or more years. Prostatic fluid previously collected and banked from each man at prostatectomy will be aliquoted and sent to our industry partner Metabolon Inc. for metabolomics analyses, and to the lab of Dr. Yegnasubramanian for epigenetic analyses. Progress to date was severely affected by the COVID-19 pandemic and the resulting requirement of remote work for many of the study team. In particular, it limited the time available to the Research Specialist to identify patients with banked prostatic fluid, determine eligibility and sample volume, and work with the PI to select appropriately matched cases and controls. We are currently continuing this process now that on-site work has increased. Other progress includes approval of the protocol by the Johns Hopkins IRB and by the USAMRDC Human Research Protection Office (HRPO), and finalization of the contract with Metabolon Inc.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2022
- Accession Number
- AD1172221
Entities
People
- Bruce J Trock
Organizations
- Johns Hopkins University